These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1430679)

  • 21. Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
    Kanemoto N; Goto Y; Hirosawa K; Kawai C; Kimata S; Yui Y; Yamamoto Y
    Jpn Circ J; 1991 Mar; 55(3):250-61. PubMed ID: 1903167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Califf RM; Ellis SG; Sigmon KN; Lee KL; Leimberger JD; Topol EJ
    J Am Coll Cardiol; 1993 Dec; 22(7):1780-7. PubMed ID: 8245328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction. Comparison with recombinant t-PA.
    Kido H; Hayashi K; Uchida T; Watanabe M
    Jpn Heart J; 1995 Jan; 36(1):61-79. PubMed ID: 7760515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
    Topol EJ; Ellis SG; Califf RM; George BS; Stump DC; Bates ER; Nabel EG; Walton JA; Candela RJ; Lee KL
    J Am Coll Cardiol; 1989 Oct; 14(4):877-84. PubMed ID: 2477426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
    Genser N; Lechleitner P; Maier J; Dienstl F; Artner-Dworzak E; Puschendorf B; Mair J
    Clin Chem; 1998 Feb; 44(2):209-14. PubMed ID: 9474013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
    von Hodenberg E; Kreuzer J; Hautmann M; Nordt T; Kübler W; Bode C
    Am J Cardiol; 1991 Jun; 67(16):1349-53. PubMed ID: 1828324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group.
    Muller DW; Topol EJ; Ellis SG; Woodlief LH; Sigmon KN; Kereiakes DJ; George BS; Worley SJ; Samaha JK; Phillips H
    J Am Coll Cardiol; 1991 Dec; 18(7):1594-601. PubMed ID: 1960302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.
    Nagao K; Satou K; Watanabe I; Arima K; Yamashita M; Ooiwa K; Kanmatsuse K
    Jpn Circ J; 1998 Feb; 62(2):111-4. PubMed ID: 9559429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
    J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group.
    Wall TC; Califf RM; Ellis SG; Sigmon K; Kereiakes D; George BS; Samaha J; Sane D; Stump DC; Stack RS
    J Am Coll Cardiol; 1993 Mar; 21(3):597-603. PubMed ID: 8436740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
    Ward SR; Sutton JM; Pieper KS; Schwaiger M; Califf RM; Topol EJ
    Am J Cardiol; 1997 Mar; 79(5):539-44. PubMed ID: 9068505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.
    Stump DC; Califf RM; Topol EJ; Sigmon K; Thornton D; Masek R; Anderson L; Collen D
    Circulation; 1989 Nov; 80(5):1222-30. PubMed ID: 2509104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy.
    Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
    Weaver WD; Hartmann JR; Anderson JL; Reddy PS; Sobolski JC; Sasahara AA
    J Am Coll Cardiol; 1994 Nov; 24(5):1242-8. PubMed ID: 7930246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
    Granger CB; Califf RM; Young S; Candela R; Samaha J; Worley S; Kereiakes DJ; Topol EJ
    J Am Coll Cardiol; 1993 Mar; 21(4):920-5. PubMed ID: 8450161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
    Grines CL; Nissen SE; Booth DC; Branco MC; Gurley JC; Bennett KA; DeMaria AN
    J Am Coll Cardiol; 1989 Sep; 14(3):573-80. PubMed ID: 2504797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the Thrombolysis in Myocardial Infarction (TIMI) Trial.
    Lehmann KG; Francis CK; Sheehan FH; Dodge HT
    J Am Coll Cardiol; 1993 Sep; 22(3):714-9. PubMed ID: 8354803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.